Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

takeda gmbh - pantoprazol - gastroezofagealni refluks - inhibitori protonske pumpe - kratkoročno liječenje simptoma refluksa (npr. žgaravica, regurgitacija kiseline) u odraslih osoba.

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin - dijabetes mellitus, tip 2 - drugs used in diabetes, dipeptidyl peptidase 4 (dpp-4) inhibitors - vipidia je indicirana u odraslih u dobi od 18 godina i starijih sa šećernom bolešću tipa 2 za poboljšanje kontrole glikemije u kombinaciji s drugim glukoze smanjuje lijekovi uključujući inzulin, kada ovo uz dijetu i tjelovježbu, ne pružaju adekvatnu regulacija glikemije (vidjeti dijelove 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - anagrelide - trombocitemija, esencijalna - antineoplastična sredstva - xagrid je indiciran za smanjenje povišenih trombocita u rizičnih eterično-thrombocythaemia (et) bolesnika koji ne podnose da njihova trenutna terapija ili čiji povišenih trombocita ne umanjuju na prihvatljivu razinu njihove trenutne terapije. u grupu rizika patientan na rizik i određuje jedno ili više od sljedećeg:>60 godina;broj trombocita >1000 x 109/l;ili povijest događaja thrombohaemorrhagic .

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedemas, nasljedni - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - karcinom, ne-malih stanica pluća - antineoplastična sredstva - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - infekcije citomegalovirusa - antivirusni lijekovi za sustavnu uporabu - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antivirusnih lijekova.

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - denga - cjepiva - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

takeda pharmaceuticals international ag - ikatiban - angioedemas, nasljedni - srčana terapija - firazyr je indiciran za simptomatsko liječenje akutnog napada nasljednog angioedema (hae) u odraslih osoba (sa c1 esteraze nedostatak).

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacin hidroklorid - deficit poremećaja pozornosti s hiperaktivnošću - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv bi trebao biti korišten kao dio integriranog programa za liječenje adhd-om, kao i obično, uključujući psihološke, obrazovne i socijalne mjere.

Խորվաթիա - խորվաթերեն - HALMED (Agencija za lijekove i medicinske proizvode)

cheplapharm arzneimittel gmbh, ziegelhof 24, greifswald, njemačka - urapidil - kapsula s produljenim oslobađanjem, tvrda - 30 mg - urbroj: jedna kapsula s produljenim oslobađanjem, tvrda sadrži 30 mg urapidila